Cargando…

Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial

INTRODUCTION: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial failed to demonstrate a mortality difference for hemorrhaging patients receiving a balanced (1:1:1) vs a 1:1:2 resuscitation at 24 hours and 30 days. Recent guidelines recommend earlier mortality end points for...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammers, Daniel, Rokayak, Omar, Uhlich, Rindi, Sensing, Thomas, Baird, Emily, Richman, Joshua, Holcomb, John B, Jansen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414081/
https://www.ncbi.nlm.nih.gov/pubmed/37575614
http://dx.doi.org/10.1136/tsaco-2023-001091
_version_ 1785087268619288576
author Lammers, Daniel
Rokayak, Omar
Uhlich, Rindi
Sensing, Thomas
Baird, Emily
Richman, Joshua
Holcomb, John B
Jansen, Jan
author_facet Lammers, Daniel
Rokayak, Omar
Uhlich, Rindi
Sensing, Thomas
Baird, Emily
Richman, Joshua
Holcomb, John B
Jansen, Jan
author_sort Lammers, Daniel
collection PubMed
description INTRODUCTION: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial failed to demonstrate a mortality difference for hemorrhaging patients receiving a balanced (1:1:1) vs a 1:1:2 resuscitation at 24 hours and 30 days. Recent guidelines recommend earlier mortality end points for hemorrhage-control trials, and the use of contemporary statistical methods. The aim of this post hoc analysis of the PROPPR trial was to evaluate the impact of a balanced resuscitation strategy at early resuscitation time points using a Bayesian analytical framework. METHODS: Bayesian hierarchical models were created to assess mortality differences at the 1, 3, 6, 12, 18, and 24 hours time points between study cohorts. Posterior probabilities and Bayes factors were calculated for each time point. RESULTS: A 1:1:1 resuscitation displayed a 96%, 99%, 94%, 92%, 96%, and 94% probability for mortality benefit at 1, 3, 6, 12, 18, and 24 hours, respectively, when compared with a 1:1:2 approach. Associated Bayes factors for each respective time period were 21.2, 142, 14.9, 11.4, 26.4, and 15.5, indicating ‘strong’ to ‘decisive’ supporting evidence in favor of balanced transfusions. CONCLUSION: This analysis provides evidence in support that a 1:1:1 resuscitation has a high probability of mortality benefit when compared with a 1:1:2 strategy, especially at the newly defined more proximate time points during the resuscitative period. Researchers should consider using Bayesian approaches, along with more proximate end points when assessing hemorrhage-related mortality, for the analysis of future clinical trials. LEVEL OF EVIDENCE: Level III/Therapeutic.
format Online
Article
Text
id pubmed-10414081
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104140812023-08-11 Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial Lammers, Daniel Rokayak, Omar Uhlich, Rindi Sensing, Thomas Baird, Emily Richman, Joshua Holcomb, John B Jansen, Jan Trauma Surg Acute Care Open Original Research INTRODUCTION: The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial failed to demonstrate a mortality difference for hemorrhaging patients receiving a balanced (1:1:1) vs a 1:1:2 resuscitation at 24 hours and 30 days. Recent guidelines recommend earlier mortality end points for hemorrhage-control trials, and the use of contemporary statistical methods. The aim of this post hoc analysis of the PROPPR trial was to evaluate the impact of a balanced resuscitation strategy at early resuscitation time points using a Bayesian analytical framework. METHODS: Bayesian hierarchical models were created to assess mortality differences at the 1, 3, 6, 12, 18, and 24 hours time points between study cohorts. Posterior probabilities and Bayes factors were calculated for each time point. RESULTS: A 1:1:1 resuscitation displayed a 96%, 99%, 94%, 92%, 96%, and 94% probability for mortality benefit at 1, 3, 6, 12, 18, and 24 hours, respectively, when compared with a 1:1:2 approach. Associated Bayes factors for each respective time period were 21.2, 142, 14.9, 11.4, 26.4, and 15.5, indicating ‘strong’ to ‘decisive’ supporting evidence in favor of balanced transfusions. CONCLUSION: This analysis provides evidence in support that a 1:1:1 resuscitation has a high probability of mortality benefit when compared with a 1:1:2 strategy, especially at the newly defined more proximate time points during the resuscitative period. Researchers should consider using Bayesian approaches, along with more proximate end points when assessing hemorrhage-related mortality, for the analysis of future clinical trials. LEVEL OF EVIDENCE: Level III/Therapeutic. BMJ Publishing Group 2023-08-09 /pmc/articles/PMC10414081/ /pubmed/37575614 http://dx.doi.org/10.1136/tsaco-2023-001091 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Lammers, Daniel
Rokayak, Omar
Uhlich, Rindi
Sensing, Thomas
Baird, Emily
Richman, Joshua
Holcomb, John B
Jansen, Jan
Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title_full Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title_fullStr Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title_full_unstemmed Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title_short Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
title_sort balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the proppr trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414081/
https://www.ncbi.nlm.nih.gov/pubmed/37575614
http://dx.doi.org/10.1136/tsaco-2023-001091
work_keys_str_mv AT lammersdaniel balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT rokayakomar balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT uhlichrindi balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT sensingthomas balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT bairdemily balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT richmanjoshua balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT holcombjohnb balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial
AT jansenjan balancedresuscitationandearliermortalityendpointsbayesianposthocanalysisofthepropprtrial